| The shot developed by the German firm CureVac uses messenger RNA technology similar to the highly effective vaccines developed by Pfizer-BioNTech and Moderna. But the final analysis of the CureVac vaccine, reported in a company news release, shows the two-dose regimen was only 48 percent effective overall in preventing symptomatic illness in a study, although it provided a strong shield of protection against more serious cases and those requiring hospitalization in adults younger than 60. | 
